Open-access OCTA tools showed similar reliability, but different vessel density values in glaucoma; researchers advise using ...

A retrospective study of 165 surgically treated patients found that machine-learning analysis of whole-slide images linked ...

A factor model isn’t a shopping list of traits investors hope will outperform. It’s a testable portfolio-design hypothesis: ...

October 13, 2026, Japan Standard Time. This report analyzes the new optical communication module initiative announced by NVIDIA and Cisco on October 12. We treat technical announcements, design ...

It's been a nice little heater of a run for this column over the past three slates, as we've hit multiple touchdown scorers and nailed the Rams on Monday night (the Giants props were unfortunately ...

Joint demonstration showcases a massively parallel optical die-to-die architecture designed to extend high-bandwidth, low-power, low-latency connectivity over multimode fiber MALAGA, Spain--(BUSINESS ...

Some doctors and influencers say women shouldn’t wait until their 60s for a DEXA scan. Here’s what to consider before getting one. By Danielle Friedman In the last few years, there’s been a cultural ...

Following nearly 10,000 older women for 10 years, researchers found that tea drinking was associated with slightly higher hip bone density. Moderate coffee consumption did not appear harmful, but ...

In this Ask the Analyst series, I’m answering your questions about investing, personal finance, and retirement planning. Today’s question: Is Jack Bogle’s advice of “age-in-bonds” total portfolio ...

Nick Blackmer is a librarian, fact-checker, and researcher with more than 20 years of experience in consumer-facing health and wellness content. Routine osteoporosis generally begins at age 65 for ...

Osimertinib with/without chemotherapy in patients with persistent ctDNA EGFR mutant (EGFRm) NSCLC at 3 weeks after 1L osimertinib: A randomized phase II study (FLAME study). This is an ASCO Meeting ...

Two-cycle versus three-cycle induction chemotherapy followed by concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: A phase III randomized noninferiority trial. This is ...